Safety of CT-Guided Bone Marrow Biopsy in Thrombocytopenic Patients: A Retrospective Review
Autor: | Jamil Armaly, Alex Pinizzotto, Michael Valente, Joseph Limback, Thomas J. Ward, Melissa Kendall, Bo Liu, Vincent Grekoski, Jeremy R. Burt |
---|---|
Rok vydání: | 2017 |
Předmět: |
Adult
Image-Guided Biopsy Male medicine.medical_specialty Adolescent Radiography Platelet Transfusion 030204 cardiovascular system & hematology Radiography Interventional 03 medical and health sciences 0302 clinical medicine Bone Marrow Risk Factors Biopsy medicine Humans Radiology Nuclear Medicine and imaging Platelet Aged Retrospective Studies Aged 80 and over medicine.diagnostic_test Platelet Count business.industry Retrospective cohort study Middle Aged Thrombocytopenia Surgery Platelet transfusion medicine.anatomical_structure Population study Female Patient Safety Bone marrow Tomography X-Ray Computed Cardiology and Cardiovascular Medicine business 030215 immunology |
Zdroj: | Journal of Vascular and Interventional Radiology. 28:1727-1731 |
ISSN: | 1051-0443 |
DOI: | 10.1016/j.jvir.2017.08.009 |
Popis: | To test the hypothesis that computed tomography (CT)-guided bone marrow biopsy in patients with a platelet count between 20,000/uL and 50,000/uL is safe and that preprocedure platelet transfusion is unnecessary.This single-center retrospective study included bone marrow biopsies performed between May 2009 and May 2016. The study population included 981 patients-age range, 15-93 years; average age, 57 years; 505 (51.5%) men; and 476 (48.5%) women. One hundred eighty-seven biopsies were performed in patients with a platelet count of 20,000-50,000/μL; 33 were performed in patients with a platelet count of20,000/μL. The primary endpoint was hemorrhagic complications, Society of Interventional Radiology (SIR) complication class C or above. The complication rates in thrombocytopenic patients were compared to patients with a platelet count of ≥ 50,000/uL. Ninety-five percent confidence intervals (CIs) for the complication rate in each group were also calculated.There were no SIR class C or above postprocedure bleeding-related complications, including interventions or transfusions. For patients with a platelet count of20,000/μL and of 20,000-50,000/μL, hemorrhagic complications rates were 0% (95% CI: 0-9.1%) and 0% (95% CI: 0-1.6%), respectively.CT-guided bone marrow biopsy is safe in thrombocytopenic patients, with a hemorrhagic complication rate below 1.6% for patients with a platelet count of 20,000-50,000/μL. Routine preprocedure platelet transfusion may not be necessary for patients with a platelet count of 20,000-50,000/μL. |
Databáze: | OpenAIRE |
Externí odkaz: |